336818-70-3

Upstream product

• 878541-74-3 1-tert-butyl 2-methyl 2-(4-cyanobenzyl)pyrrolidine-1,2-dicarboxylate 
• 874-86-2 4-cyanobenzyl chloride 
• 59936-29-7 (S)-N-(tert-butoxycarbonyl)proline methyl ester 

Downstream Products

• 878541-88-9 methyl 2-(4-cyanobenzyl)-1-[(3,5-dichlorophenyl)acetyl]pyrrolidine-2-carboxylate 
• 481704-16-9 N-[[3-chloro-5-(1-pyrrolyl)phenyl]carbamoyl]-2-(4-bromobenzyl)proline methyl ester 
• 336819-04-6 C₃₇H₃₂Cl₂N₄O₇ 
• 878541-92-5 7a-(4-cyanobenzyl)-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7a-tetrahydro-1H-pyrrolizin-7-yl trifluoromethanesulfonate 
• 936227-31-5 7a-(4-cyanobenzyl)-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7a-tetrahydro-1H-pyrrolizine-7-carbonitrile 
• 878541-90-3 4-{[6-(3,5-dichlorophenyl)-7-hydroxy-5-oxo-2,3-dihydro-1H-pyrrolizin-7a(5H)-yl]methyl}benzonitrile 

Relevant academic research and scientific papers

Design of LFA-1 antagonists based on a 2,3-dihydro-1H-pyrrolizin-5(7aH)-one scaffold

A new class of lymphocyte function-associated antigen-1 (LFA-1) antagonists is described. Elaboration of the 2,3-dihydro-1H-pyrrolizin-5(7aH)-one scaffold resulted in the synthesis of potent inhibitors of the LFA-1/ICAM-1 interaction. Along with the in vi

Pyrrolizine compounds useful as anti-inflammatory agents

Pyrrolizine compounds having the formula (I), or pharmaceutically-acceptable salts thereof, are effective in treating inflammatory or immune diseases, where A is a four- to seven-membered saturated ring, K is O or S, and R1, R2, Rsu

INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION

The present invention relates to a compound of formula: (I), or a pharmaceutically acceptable salt thereof.